相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry
J. Zweegers et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Bruce E. Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis
Lluis Puig et al.
DERMATOLOGY (2015)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
PASI90 response: the new standard in therapeutic efficacy for psoriasis
L. Puig
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Diet and physical exercise in psoriasis: a randomized controlled trial
L. Naldi et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE
J. Zweegers et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice
N. H. Shear et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
J. M. P. A. van den Reek et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis
S. P. Menting et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis
J. M. P. A. van den Reek et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial
Nawaf Al-Mutairi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions
J. Spertino et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
P. L. Mattei et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
J. M. Carrascosa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study
M. Esposito et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients
P. P. M. van Lumig et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men
David Hagg et al.
PLOS ONE (2013)
Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab
Hideshi Torii et al.
JOURNAL OF DERMATOLOGY (2012)
Implementing treatment goals for successful long-term management of psoriasis
U. Mrowietz
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab
Kristian Reich et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
